Nanobiotix reports Phase 1 NSCLC data for JNJ-1900 showing 79% one-year locoregional control rate
NBTX•Phase 1 NSCLC results presented at IASLC WCLC 2026
Nanobiotix reported full-cohort Phase 1 results for JNJ-1900 (NBTXR3) in recurrent, inoperable NSCLC; data were presented at IASLC WCLC 2026.
- Treatment was delivered without dose-limiting toxicities; no severe side effects were tied to JNJ-1900 or the injection procedure.
- Investigators saw signs of meaningful local disease control, supporting use of a lower repeat-radiation dose than patients previously received.
- The study’s dose-escalation and expansion enrollment is complete; additional patient enrollment is planned following the results.
